Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Cyclophosphamide Maintenance in MM
NCT06324266Phase 3Recruiting
- Sponsor
- Jinling Hospital
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide in multiple myeloma (MM) (2 arms), sponsored by Jinling Hospital. Primary endpoint: Progression-Free Survival at 3 years. Started Apr 2023; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06324266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324266.